Dengue Disease
by Trina M. Girimont, ARNP, COHN-S O n July 13, 2010, the Centers for Disease Control and Prevention (CDC) estimated that 5% of Key West, Florida, residents had recent exposure to dengue (CDC, 2010b) . Dengue is caused by one of four distinct, but related, viruses transmitted between humans via female Aedes aegypti and Aedes albopictus mosquitoes, present in tropical and subtropical areas (World Health Organization [WHO], 2009b) . Infected humans are the main carriers and multipliers of the virus; all age groups are susceptible to infection. Dengue is currently the most rapidly spreading mosquito-borne illness, causing an estimated 50 to 100 million infections and 26,000 deaths annually (WHO, 2009a (WHO, , 2009b . Dengue is the leading cause of acute febrile illnesses among U.S. travelers returning from South America, Asia, and the Caribbean (CDC, 2010b) . These travelers are often infectious on returning home and therefore capable of transmitting the disease. Due to concerns over potential transmission of dengue via blood transfusion, it was deemed a nationally notifiable disease in 2010 (CDC, 2010c) .
Dengue infection with any of the four serotypes can produce the full continuum of illness, ranging from mild, nonspecific symptoms, to classic dengue fever, to the most serious forms of the infection-dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Up to half of all infections are asymptomatic (CDC, 2010a). The bite from one infected mosquito can result in infection. Dengue infection should be considered when evaluating any individual with febrile illness who lives in or has traveled to a tropical or subtropical area within the past 2 weeks. The infection usually has three phases: febrile, critical, and recovery (WHO, 2009b) .
DHF is characterized by the acute onset of flu-like symptoms 3 to 14 days after a bite. The febrile phase includes a high temperature (> 38.3°C) and possibly frontal headache, facial flushing, arthralgias, myalgias, retro-orbital pain, rash, nausea, anorexia, and bone pain. A positive tourniquet test increases the likelihood of dengue (WHO, 2009b) . Definitive diagnosis requires detection of dengue-specific antibodies or isolation of the virus (CDC, 2010b). Hemorrhagic manifestations, including petechiae, hematomas, epistaxis, and gingival bleeding, are usually mild. Febrile phase symptoms usually begin to decrease after 6 to 7 days, but weakness and malaise may persist for several weeks.
DHF and DSS are potential lifethreatening sequelae to dengue. DHF critical phase begins 24 to 48 hours after fever subsides and is defined by four criteria: (1) fever or recent fever lasting 2 to 7 days; (2) any hemorrhagic sign or symptom; (3) thrombocytopenia; and (4) evidence of increased vascular permeability (CDC, 2010a). Persistent vomiting, severe abdominal pain, and difficulty breathing may develop. Swings in body temperature (hypo-to hyperthermia) and mental status changes may occur. Severe hemorrhagic symptoms may progress to vaginal or intracranial bleeding. In mild to moderate DHF cases, symptoms will begin to dissipate once the fever subsides.
DSS is defined as any case meeting the four criteria with circulatory failure and symptoms of cold, clammy skin, hypotension, and widening pulse pressure. The mortality rate can be as high as 10% without rapid disease recognition and treatment.
No pharmacologic or curative agents or vaccine exists for dengue, DHF, or DSS. Rest, hydration, monitoring of urine output, and antipyretic medications with avoidance of aspirin and nonsteroidal anti-inflammatory agents, which may increase risk of hemorrhage, are recommended for mild to moderate symptoms. Management of DSS can be complex.
Primary prevention of dengue centers on protection from insect bites. Vessels or objects (e.g., planters, buckets, barrels, drainage gutters) containing standing water should be emptied to limit mosquito breeding areas.
Employees who live or work in or travel to areas where dengue is prevalent should avoid the outdoors during daylight hours, when A. aegypti and A. albopictus activity is high. Accommodations with screens or air conditioning should be considered whenever possible. Clothing must cover exposed skin. Insecticides such as DEET or Picardin must be used according to manufacturer instructions. Insecticide-treated clothing and materials (i.e., bed netting, window screens, curtains) are encouraged (WHO, 2009b) .
